Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Old API Wind-down Ltd - Ordinary Shares ARLZQ

Healthcare Drug Manufacturers - Major Drug Manufacturers - Specialty & Generic
"Old API Wind-down Ltd, formerly Aralez Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in the acquisition, development, and commercialization of products primarily in cardiovascular, pain management and other specialty areas. Its key products include Fiorinal, Proferrin, Fibricor, Uracyst and Neovisc, Cambia and other marketed products. The company currently operates in two geographical markets, the United States and Canada. The firm generates most of its reven


OTCPK:ARLZQ - Post by User

Old API Wind-down Ltd - Ordinary Shares > Seeking alpha
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(109)
•••
Comment by mjh9413on Oct 07, 2016 2:31pm
92 Views
Post# 25323664

RE:RE:RE:RE:RE:RE:RE:RE:RE:Seeking alpha

RE:RE:RE:RE:RE:RE:RE:RE:RE:Seeking alphaSorry you don't get my main point which is clearly, are they overpaying for latest AZ drug. If the idea is that they should rely on Yosprala cash generation to ensure they can cover P&I costs then you are confirming they most probably are overpaying. You want them to deal with new purchases on the basis that each one is profitable on its own. That is rhetorical. I don't need an answer.
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities